journal
https://read.qxmd.com/read/38901648/neoadjuvant-and-adjuvant-treatment-for-early-stage-resectable-non-small-cell-lung-cancer-nsclc-consensus-recommendations-from-the-international-association-for-the-study-of-lung-cancer-iaslc
#1
JOURNAL ARTICLE
Jonathan D Spicer, Tina Cascone, Murry W Wynes, Myung-Ju Ahn, Sanja Dacic, Enriqueta Felip, Patrick M Forde, Kristin A Higgins, Mark G Kris, Tetsuya Mitsudomi, Mariano Provencio, Suresh Senan, Benjamin J Solomon, Ming S Tsao, Masahiro Tsuboi, Heather A Wakelee, Yi-Long Wu, James Chih-Hsin Yang, Caicun Zhou, David H Harpole, Karen L Kelly
Advances in the multidisciplinary care of early-stage resectable non-small cell lung cancer (rNSCLC) are emerging at an unprecedented pace. Numerous phase 3 trials produced results that have transformed patient outcomes for the better, yet these findings also require important modifications to the patient treatment journey trajectory and re-organization of care pathways. Perhaps most notably, the need for multispecialty collaboration for this patient population has never been greater. These rapid advances have inevitably left us with important gaps in knowledge for which definitive answers will only become available in several years...
June 18, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38880172/prevalence-of-egfr-mutations-in-patients-with-resected-stage-i-iii-nsclc-results-from-the-early-egfr-study
#2
JOURNAL ARTICLE
Ross A Soo, Thanyanan Reungwetwattana, Herman Andres Perroud, Ullas Batra, Saadettin Kilickap, Luis Fernando Tejado Gallegos, Natalia Donner, Mohamed Elsayed, Reto Huggenberger, Dao Van Tu
BACKGROUND: There is limited literature on the prevalence of EGFR mutations in early-stage non-small cell lung cancer (NSCLC). EARLY-EGFR (NCT04742192), a cross-sectional study, determined the prevalence of EGFR mutations in early-stage NSCLC. METHODS: This non-interventional, real-world study enrolled consecutive patients with resected stage IA-IIIB (American Joint Committee on Cancer 8th edition) NSCLC from 14 countries across Asia, Latin America, and Middle East and Africa...
June 14, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38866326/mutational-characteristics-and-clinical-outcomes-for-lung-adenocarcinoma-with-egfr-germline-mutations
#3
JOURNAL ARTICLE
Kelsey Pan, Jennifer Owens, Yasir Elamin, Charles Lu, Mark Routbort, Jianjun Zhang, Frank Fossella, Marcelo V Negrao, Mehmet Altan, Jenny Pozadzides, Ferdinandos Skoulidis, Anne Tsao, Tina Cascone, John V Heymach, Edwin Ostrin, Xiuning Le
BACKGROUND: Germline mutations driving lung cancer have been infrequently reported in literature, with EGFR T790M being a known germline mutation identified in 1% of NSCLC. Typically, a somatic EGFR mutation is acquired to develop lung adenocarcinoma. Osimertinib has become standard-of-care treatment for EGFR T790M-positive lung cancer. METHODS: We perform a retrospective analysis through the Lung Cancer Moon Shot GEMINI database at the UT MD Anderson Cancer Center...
June 10, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38788924/stereotactic-body-radiotherapy-for-centrally-located-inoperable-early-stage-nsclc-eortc-22113-08113-lungtech-phase-ii-trial-results
#4
JOURNAL ARTICLE
Antonin Levy, Sonja Adebahr, Coen Hurkmans, Merina Ahmed, Shahreen Ahmad, Matthias Guckenberger, Xavier Geets, Yolande Lievens, Maarten Lambrecht, Nicolas Pourel, Victor Lewitzki, Krzysztof Konopa, Kevin Franks, Rafal Dziadziuszko, Fiona McDonald, Catherine Fortpied, Enrico Clementel, Béatrice Fournier, Stefania Rizzo, Christian Fink, Oliver Riesterer, Heike Peulen, Nicolaus Andratschke, Alan McWilliam, Eleni Gkika, Tanja Schimek-Jasch, Anca-Ligia Grosu, Cécile Le Pechoux, Corinne Faivre-Finn, Ursula Nestle
BACKGROUND: The international EORTC phase II single-arm LungTech trial 22113-08113 assessed safety and efficacy of stereotactic body radiotherapy (SBRT) in patients with centrally located early-stage non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with inoperable non-metastatic central NSCLC (T1-T3 N0 M0, ≤7cm) were included. After prospective central imaging review and radiation therapy quality assurance (RTQA) for any eligible patient, SBRT (8x7...
May 22, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38762120/a-real-world-assessment-of-stage-i-lung-cancer-through-electronic-nose-technology
#5
JOURNAL ARTICLE
Gaetano Rocco, Giorgio Pennazza, Kay See Tan, Stijn Vanstraelen, Marco Santonico, Robert J Corba, Bernard J Park, Smita Sihag, Matthew J Bott, Pierfilippo Crucitti, James M Isbell, Michelle S Ginsberg, Hallie Weiss, Raffaele Antonelli Incalzi, Panaiotis Finamore, Filippo Longo, Alessandro Zompanti, Simone Grasso, Stephen B Solomon, Alain Vincent, Alexa McKnight, Michael Cirelli, Carmela Voli, Susan Kelly, Mario Merone, Daniela Molena, Katherine Gray, James Huang, Valerie W Rusch, Manjit S Bains, Robert J Downey, Prasad S Adusumilli, David R Jones
INTRODUCTION: Electronic nose (E-nose) technology has demonstrated excellent sensitivity and specificity in the setting of lung cancer screening. However, the performance of E-nose specifically for early-stage tumors remains unclear. Therefore, the aim of our study was to assess the diagnostic performance of E-nose technology in clinical stage I lung cancer. METHODS: This Phase-IIc trial (NCT04734145) included patients diagnosed with a single ≥50% solid stage I nodule...
May 16, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38734073/the-iaslc-mesothelioma-staging-project-proposals-for-the-n-descriptors-in-the-forthcoming-9th-edition-of-the-tnm-classification-for-pleural-mesothelioma
#6
JOURNAL ARTICLE
Andrea Bille, R Taylor Ripley, Dorothy J Giroux, Ritu R Gill, Hedy L Kindler, Anna K Nowak, Isabelle Opitz, Harvey I Pass, Andrea Wolf, David Rice, Valerie W Rusch
INTRODUCTION: The International Association for the Study of Lung Cancer developed an international database to inform potential revisions in the 9th edition of the Tumor, Node, Metastasis classification of diffuse pleural mesothelioma (PM). This study analyzed the clinical and pathological N categories to determine whether revisions were indicated relative to the 8th edition staging system. METHODS: Of 7,338 PM cases diagnosed 2013 to 2022, 3,598 met all inclusion criteria for planned analyses...
May 9, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38734072/the-iaslc-pleural-mesothelioma-staging-project-proposal-for-revision-of-the-tnm-stage-groupings-in-the-forthcoming-ninth-edition-of-the-tnm-classification-for-pleural-mesothelioma
#7
JOURNAL ARTICLE
Anna K Nowak, Dorothy J Giroux, Megan Eisele, Adam Rosenthal, Andrea Bille, Ritu R Gill, Hedy L Kindler, Harvey I Pass, David Rice, R Taylor Ripley, Andrea Wolf, Joseph Friedberg, Katherine Nishimura, Valerie W Rusch
INTRODUCTION: The eighth edition of the tumor, node and metastases (TNM) classification of pleural mesothelioma (PM) saw substantial changes in T and N components and stage groupings. The International Association for the Study of Lung Cancer collected data into a multinational database in order to further refine this classification. This 9th edition proposal incorporates changes proposed in the clinical (c)T component, but not the pathologic (p)T component, to include size criteria, and further refines TNM stage groupings for PM...
May 9, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38729426/brief-report-updated-data-from-imscin001-part-2-a-randomized-phase-iii-study-of-subcutaneous-versus-intravenous-atezolizumab-in-patients-with-locally-advanced-metastatic-nsclc
#8
JOURNAL ARTICLE
Mauricio Burotto, Zanete Zvirbule, Renzo Alvarez, Busayamas Chewaskulyong, Luis A Herraez-Baranda, Esther Shearer-Kang, Xiaoyan Liu, Nadia Tosti, Patrick Williams, Amparo Yovanna Castro Sanchez, James Zanghi, Enriqueta Felip
INTRODUCTION: Subcutaneous atezolizumab is approved for the treatment of various solid tumors. Previous results from the IMscin001 study (NCT03735121) demonstrated that the pharmacokinetics, efficacy, immunogenicity, and safety of subcutaneous and intravenous atezolizumab were consistent (data cutoff: April 26, 2022). We present updated data from this trial (data cut-off: 16 January 2023). METHODS: Eligible patients aged ≥18 years with locally advanced/metastatic NSCLC were randomized (2:1) to receive atezolizumab subcutaneously (1875 mg, n=247) or intravenously (1200 mg, n=124) every 3 weeks...
May 8, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38723776/tracing-tumor-heterogeneity-of-pleomorphic-carcinoma-of-the-lung
#9
JOURNAL ARTICLE
Luca Roma, Caner Ercan, Floriana Conticelli, Nalan Akyürek, Spasenija Savic Prince, Kirsten D Mertz, Joachim Diebold, Didier Lardinois, Salvatore Piscuoglio, Charlotte Ky Ng, Lukas Bubendorf
BACKGROUND: Pulmonary pleomorphic carcinoma (PPC) is an aggressive and highly heterogeneous non-small-cell lung carcinoma whose underlying biology is still poorly understood. METHODS: Forty-two tumor areas from 20 PPC patients were microdissected, including 39 primary tumors and 3 metastases and the histologically distinct components were subjected to whole exome sequencing (WES) separately. We further performed in silico analysis of microdissected bulk RNAseq and methylation data of 28 samples from 14 PPC patients...
May 7, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38642841/pembrolizumab-plus-chemotherapy-for-metastatic-nsclc-with-programmed-cell-death-ligand-1-tumor-proportion-score-less-than-1-pooled-analysis-of-outcomes-after-five-years-of-follow-up
#10
JOURNAL ARTICLE
Shirish M Gadgeel, Delvys Rodríguez-Abreu, Balazs Halmos, Marina C Garassino, Takayasu Kurata, Ying Cheng, Erin Jensen, Mark Shamoun, Kumar Rajagopalan, Luis Paz-Ares
BACKGROUND: We report long-term outcomes from a pooled analysis of patients with previously untreated metastatic NSCLC with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) less than 1% enrolled in phase III studies of pembrolizumab plus chemotherapy versus placebo plus chemotherapy. METHODS: This exploratory pooled analysis included individual patient data from the KEYNOTE-189 global (NCT02578680) and Japan extension (NCT03950674) studies of metastatic nonsquamous NSCLC without EGFR or ALK alterations and the KEYNOTE-407 global (NCT02775435) and People's Republic of China extension (NCT03875092) studies of metastatic squamous NSCLC...
April 18, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38614456/validation-study-for-the-n-descriptor-of-the-newly-proposed-ninth-edition-of-the-tnm-staging-system-proposed-by-the-international-association-for-the-study-of-lung-cancer
#11
JOURNAL ARTICLE
In Ha Kim, Geun Dong Lee, Sehoon Choi, Hyeong Ryul Kim, Yong-Hee Kim, Dong Kwan Kim, Seung-Il Park, Jae Kwang Yun
INTRODUCTION: The aim of this study was to validate the discriminatory ability and clinical utility of the N descriptor of the newly proposed ninth edition of the TNM staging system for lung cancer in a large independent cohort. METHODS: We retrospectively analyzed patients who underwent curative surgery for NSCLC between January 2004 and December 2019. The N descriptor of patients included in this study was retrospectively reclassified based on the ninth edition of the TNM classification...
April 16, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38615940/clinical-utility-of-circulating-tumor-dna-in-patients-with-advanced-kras-g12c-mutated-non-small-cell-lung-cancer-treated-with-sotorasib
#12
JOURNAL ARTICLE
Sophie M Ernst, Ronald van Marion, Peggy N Atmodimedjo, Evert de Jonge, Ron H J Mathijssen, Marthe S Paats, Peter de Bruijn, Stijn L Koolen, Jan H von der Thüsen, Joachim G J V Aerts, Ron H N van Schaik, Hendrikus J Dubbink, Anne-Marie C Dingemans
INTRODUCTION: For patients with KRASG12C-mutated NSCLC who are treated with sotorasib, there is a lack of biomarkers to guide treatment decisions. We therefore investigated the clinical utility of pre-treatment and on-treatment circulating tumor DNA (ctDNA), as well as treatment-emergent alterations upon disease progression. METHODS: Patients with KRASG12C-mutated NSCLC treated with sotorasib were prospectively enrolled in our biomarker study (NCT05221372). Plasma samples were collected prior to sotorasib treatment, at first response evaluation and at disease progression...
April 12, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38615939/treatment-response-biomarkers-working-towards-personalised-radiotherapy-for-lung-cancer
#13
REVIEW
Ashley Horne, Ken Harada, Katherine D Brown, Kevin Lee Min Chua, Fiona McDonald, Gareth Price, Paul Martin Putora, Dominic G Rothwell, Corinne Faivre-Finn
Due to major advances in the field of radiation oncology, patients with lung cancer (LC) can now receive technically individualised radiotherapy treatments. However, in the era of precision oncology, radiotherapy-based treatment selection needs to be improved as many patients do not benefit or are not offered optimum therapies. Cost-effective robust biomarkers can address this knowledge gap and lead to individuals being offered more bespoke treatments leading to improved outcome. This narrative review discusses some of the current achievements and challenges in the realisation of personalised radiotherapy delivery in patients with LC...
April 12, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38608933/survival-outcome-after-surgery-in-patients-with-thymoma-distant-recurrence
#14
JOURNAL ARTICLE
Marco Chiappetta, Carolina Sassorossi, Dania Nachira, Filippo Lococo, Elisa Meacci, Enrico Ruffini, Francesco Guerrera, Paraskevas Lyberis, Vittorio Aprile, Marco Lucchi, Marcello Carlo Ambrogi, Diana Bacchin, Andrea Dell'Amore, Carlotta Marino, Giovannimaria Comacchio, Gabriella Roca, Federico Rea, Stefano Margaritora
OBJECTIVE: Aim of this study is to describe characteristics and survival outcome of patients who underwent surgical treatment for distant thymoma relapse according to the International Thymic Malignancy Interest Group definition(ITMIG). METHODS: Data of patients affected by thymoma recurrence from 4 different Institution were collected and retrospectively reviewed.Patients with loco-regional metastases, who underwent non-surgical therapies and with incomplete data on follow-up were excluded...
April 10, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38608932/recommendations-for-post-operative-radiotherapy-after-complete-resection-of-thymoma-a-french-delphi-consensus-initiative
#15
JOURNAL ARTICLE
Clémence Basse, Jonathan Khalifa, François Thillays, Cécile Le Pechoux, Jean-Michel Maury, Pierre-Emmanuel Bonte, Alexandre Coutte, Nicolas Pourel, Vincent Bourbonne, Olivier Pradier, Aurélie Belliere, Florence Le Tinier, Mélanie Deberne, Ronan Tanguy, Fabrice Denis, Laetitia Padovani, Audrey Zaccariotto, Thierry Molina, Lara Chalabreysse, Geoffrey Brioude, Bertrand Delatour, Jean-Christophe Faivre, Kim Cao, Philippe Giraud, François-Georges Riet, Sébastien Thureau, Delphine Antoni, Carole Massabeau, Audrey Keller, Emilie Bonnet, Delphine Lerouge, Etienne Martin, Nicolas Girard, Angela Botticella
BACKGROUND: Thymomas are rare intrathoracic malignancies that can relapse after surgery. Whether or not Post-Operative Radiotherapy (PORT) should be delivered after surgery remains a major issue. RADIORYTHMIC is an ongoing, multicenter, randomized phase 3 trial addressing this question in patients with completely R0 resected Masaoka-Koga stage IIb/III thymoma. Experts in the field met to develop recommendations for PORT. METHODS: A scientific committee from the RYTHMIC network identified key issues regarding the modalities of PORT in completely resected thymoma...
April 10, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38583771/genome-wide-analysis-identifies-nuclear-factor-1c-as-a-novel-transcription-factor-and-potential-therapeutic-target-in-small-cell-lung-cancer
#16
JOURNAL ARTICLE
Vivek Shukla, Haitao Wang, Lyuba Varticovski, Songjoon Baek, Ruihong Wang, Xinwei Wu, Frank Echtenkamp, Frank Villa Hernandez, Katherine P Prothro, Sudheer K Gara, Mary R Zhang, Stephanie Shiffka, Razi Raziuddin, Leonard M Neckers, W Marston Linehan, Haobin Chen, Gordon L Hager, David S Schrump
BACKGROUND: Recent insights regarding mechanisms mediating stemness, heterogeneity, and metastatic potential of lung cancers have yet to be fully translated to effective regimens for the treatment of these malignancies. This study sought to identify novel targets for lung cancer therapy. METHODS: Transcriptomes and DNA methylomes of 14 SCLC and 10 NSCLC lines were compared to normal human small airway epithelial cells (SAEC) and induced pluripotent stem cell (iPSC) clones derived from SAEC...
April 5, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38569931/the-iaslc-lung-cancer-staging-project-proposals-for-revision-of-the-classification-of-residual-tumor-after-resection-for-the-forthcoming-9-th-edition-of-the-tnm-classification-of-lung-cancer
#17
JOURNAL ARTICLE
Frank C Detterbeck, Marcin Ostrowski, Hans Hoffmann, Ramón Rami-Porta, Ray U Osarogiagbon, Jessica Donnington, Maurizio Infante, Mirella Marino, Edith M Marom, Jun Nakajima, Andrew G Nicholson, Paul van Schil, William D Travis, Ming S Tsao, John G Edwards, Hisao Asamura
The goal of surgical resection is to completely remove a cancer; it is useful to have a system to describe how well this was accomplished. This is captured by the residual tumor (R) classification, which is separate from the TNM classification that describes the anatomic extent of a cancer independent of treatment. The traditional R-classification designates as R0 a complete resection, as R1 a macroscopically complete resection but with microscopic tumor at the surgical margin, and as R2 a resection that leaves gross tumor behind...
April 1, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38553005/egfr-oncogenic-mutations-in-nsclc-impair-macrophage-phagocytosis-and-mediate-innate-immune-evasion-through-up-regulation-of-cd47
#18
JOURNAL ARTICLE
Li-Yang Hu, Wei-Tao Zhuang, Mao-Jian Chen, Jun Liao, Dong-Fang Wu, Ya-Xiong Zhang, Lan-Lan Pang, Yi-Hua Huang, Tian-Qin Mao, Meng-Juan Yang, Pei-Jian Peng, Jin-Xia Liang, Liang Chen, Lin-Juan Zeng, Li Zhang, Wen-Feng Fang
INTRODUCTION: EGFR-mutated NSCLC is characterized by an immunosuppressive microenvironment that confers limited clinical effectiveness to anti-PD-1 or PD-L1 antibodies. Despite the discouraging outcomes of immunotherapy, novel immune checkpoints are constantly emerging, among which the specific vulnerability for therapeutic intervention in the context of EGFR-mutated NSCLC remains unresolved. METHODS: Data sets of patient- and cell line-levels were used for screening and mutual validation of association between EGFR mutation and a panel of immune checkpoint-related genes...
March 27, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38849170/association-between-rheumatoid-arthritis-and-the-risk-of-lung-cancer
#19
LETTER
Chi-Kuei Hsu, Chih-Cheng Lai
No abstract text is available yet for this article.
June 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38849169/finding-one-treatment-for-all-advanced-egfr-positive-nsclc-an-infinite-task
#20
LETTER
Edyta Maria Urbanska, Jens Benn Sørensen, Eric Santoni-Rugiu
No abstract text is available yet for this article.
June 2024: Journal of Thoracic Oncology
journal
journal
41363
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.